BRPI0718611A2 - Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase. - Google Patents

Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase.

Info

Publication number
BRPI0718611A2
BRPI0718611A2 BRPI0718611-8A2A BRPI0718611A BRPI0718611A2 BR PI0718611 A2 BRPI0718611 A2 BR PI0718611A2 BR PI0718611 A BRPI0718611 A BR PI0718611A BR PI0718611 A2 BRPI0718611 A2 BR PI0718611A2
Authority
BR
Brazil
Prior art keywords
oxidoredutase
xantine
inhibitors
methods
renal function
Prior art date
Application number
BRPI0718611-8A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Christopher Lademacher
Patricia Macdonald
Original Assignee
Takeda Pharmaceuticals North America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals North America Inc filed Critical Takeda Pharmaceuticals North America Inc
Publication of BRPI0718611A2 publication Critical patent/BRPI0718611A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
BRPI0718611-8A2A 2006-11-13 2007-11-13 Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase. BRPI0718611A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85850906P 2006-11-13 2006-11-13
PCT/US2007/084573 WO2008064015A1 (en) 2006-11-13 2007-11-13 Methods for preserving renal function using xanthine oxidoreductase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0718611A2 true BRPI0718611A2 (pt) 2014-02-25

Family

ID=39430048

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718611-8A2A BRPI0718611A2 (pt) 2006-11-13 2007-11-13 Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase.

Country Status (11)

Country Link
US (1) US20080269226A1 (OSRAM)
EP (1) EP2101761A4 (OSRAM)
JP (3) JP2010509372A (OSRAM)
KR (3) KR20090103879A (OSRAM)
CN (1) CN101677999A (OSRAM)
AU (1) AU2007323919A1 (OSRAM)
BR (1) BRPI0718611A2 (OSRAM)
CA (1) CA2669935A1 (OSRAM)
MX (1) MX2009004984A (OSRAM)
RU (1) RU2508099C2 (OSRAM)
WO (1) WO2008064015A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1883405A4 (en) * 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
US20070167454A1 (en) * 2005-08-03 2007-07-19 Christopher Lademacher Methods for treating hypertension
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
IT1400310B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e statine e loro uso.
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
BR112012032033A2 (pt) 2010-06-16 2017-10-31 Takeda Pharmaceuticals Usa Inc novas formas de dosagem de libertação modificada de inibidor de xantina oxidorredutase ou inibidores de xantina oxidase
US20130109726A1 (en) * 2010-06-25 2013-05-02 Teijin Pharma Limited Sustained-release therapeutic agent for hypertension and renal dysfunction
CN102372679A (zh) * 2010-08-27 2012-03-14 北京润德康医药技术有限公司 一种非布司他水溶性衍生物及其制备方法
CA2812034C (en) 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
JP5862897B2 (ja) * 2010-11-01 2016-02-16 株式会社三和化学研究所 腎機能障害の予防又は治療に用いる医薬
CN102757403B (zh) * 2011-04-27 2015-04-29 浙江九洲药业股份有限公司 一种非布索坦衍生物及其制备方法
TW201328692A (zh) * 2011-10-11 2013-07-16 Univ Osaka 脫髓鞘疾病之治療劑及預防劑
TW201334779A (zh) 2012-01-27 2013-09-01 Teijin Pharma Ltd 糖尿病的治療藥
WO2014065275A1 (ja) * 2012-10-23 2014-05-01 国立大学法人福井大学 腫瘍融解症候群の治療薬及び予防薬
CN103265636B (zh) * 2013-05-23 2015-09-16 中国药科大学 一种具有降血糖作用的新型肽
CN104548066A (zh) * 2015-01-19 2015-04-29 中国药科大学 一种具有降血糖作用的新型肽的新用途
CN105294584A (zh) * 2015-11-30 2016-02-03 中国医科大学 1-取代苯基-1h-1,2,3-三唑类化合物、制备方法及其用途
JP6732004B2 (ja) 2016-02-19 2020-07-29 国立大学法人鳥取大学 認知症治療薬または予防薬
CN106279024B (zh) * 2016-07-19 2018-09-14 华南理工大学 一种黄嘌呤氧化还原酶抑制剂及其制备方法与应用
KR20230119303A (ko) * 2022-02-07 2023-08-16 (주)인드림헬스케어 높은 혈중 요산 농도를 갖는 대상체의 만성 신장 질환의 예방 또는 치료를 위한 알로푸리놀, 페북소스타트 또는 이들의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4296122A (en) * 1975-07-09 1981-10-20 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(acyl)benzofuran-2-carboxylic acids
DE2727802A1 (de) * 1977-06-21 1979-04-19 Hoechst Ag Sulfamoyl-arylketone und verfahren zu ihrer herstellung
US4510322A (en) * 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
US4632930A (en) * 1984-11-30 1986-12-30 E. I. Du Pont De Nemours And Company Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
JPH0366669A (ja) * 1989-08-03 1991-03-22 Shionogi & Co Ltd 複素環式化合物
JP2725886B2 (ja) * 1990-11-30 1998-03-11 帝人株式会社 ２―アリールチアゾール誘導体及びその医薬組成物
US5358961A (en) * 1991-11-30 1994-10-25 Jin Ro Limited Pyrrolidine derivatives
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5514681A (en) * 1994-08-17 1996-05-07 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
US6037344A (en) * 1994-08-17 2000-03-14 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
US5770601A (en) * 1994-08-17 1998-06-23 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
AUPM835394A0 (en) * 1994-09-23 1994-10-13 King, Michael G. Dr. Method for controlling or eliminating the need to smoke tobacco, and for treating ailments which may lead to the said need
CA2190993C (en) * 1995-04-07 2004-06-01 Mikio Ota Protective agent for organ or tissue
ID21775A (id) * 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
US5965625A (en) * 1997-03-21 1999-10-12 King; Michael Glenn Compositions and methods for the control of smoking
EP1044002A4 (en) * 1997-11-07 2003-05-02 Univ Johns Hopkins METHODS FOR THE TREATMENT OF HEART CONTRACTILITY
CZ298170B6 (cs) * 1998-06-19 2007-07-11 Teijin Limited Polymorfní a amorfní modifikace 2-(3-kyan-4-isobutoxyfenyl)-4-methyl-5-thiazolkarboxylové kyseliny a zpusob jejich prípravy
US6281222B1 (en) * 1999-08-19 2001-08-28 Inotek Corporation Compositions and method for treatment of acetaminophen intoxication
US7799794B2 (en) * 2000-06-28 2010-09-21 Merck Sharp & Dohme Corp. Treatment for cardiovascular disease
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
EP1416942B1 (en) * 2001-04-18 2007-12-12 Genzyme Corporation Amine polymers for treating gout and binding uric acid
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
RU2293733C2 (ru) * 2002-01-28 2007-02-20 Фуджи Якухин Ко., Лтд. Новые 1,2,4-триазольные соединения, способы их получения и содержащие их лекарственные средства
SI1488790T1 (sl) * 2002-03-28 2014-09-30 Teijin Pharma Limited Trden pripravek, ki vsebuje eno samo kristalno a-obliko derivata tiazolkarboksilne kisline
US20060040945A1 (en) * 2002-05-17 2006-02-23 Merckle Gmbh Annellated pyrrole compounds as proton pump inhibitors for treating ulcer
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040131676A1 (en) * 2002-12-20 2004-07-08 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040122067A1 (en) * 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
WO2006028342A1 (en) * 2004-09-06 2006-03-16 Biosynergen, Inc. A novel xanthine oxidase inhibitor and a pharmaceutical composition containing the same
EP1819334A1 (en) * 2004-11-19 2007-08-22 Shiva Biomedical, LLC Methods of treating erythropoietin-resistance
EP1883405A4 (en) * 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
US20070167454A1 (en) * 2005-08-03 2007-07-19 Christopher Lademacher Methods for treating hypertension
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
CA2812034C (en) * 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat

Also Published As

Publication number Publication date
CN101677999A (zh) 2010-03-24
AU2007323919A1 (en) 2008-05-29
KR20090103879A (ko) 2009-10-01
US20080269226A1 (en) 2008-10-30
EP2101761A1 (en) 2009-09-23
JP6233899B2 (ja) 2017-11-22
KR20150024919A (ko) 2015-03-09
JP2014012726A (ja) 2014-01-23
WO2008064015A1 (en) 2008-05-29
MX2009004984A (es) 2009-09-23
KR20160031040A (ko) 2016-03-21
JP2010509372A (ja) 2010-03-25
RU2009122505A (ru) 2010-12-20
CA2669935A1 (en) 2008-05-29
RU2508099C2 (ru) 2014-02-27
JP2016188231A (ja) 2016-11-04
EP2101761A4 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
BRPI0718611A2 (pt) Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase.
BRPI0816859A2 (pt) Artigo para fumar, e, método para fabricar um artigo para fumar.
BRPI0819127A2 (pt) Método para cimentar.
DK2034856T3 (da) Drikkevaresammensætninger, der omfatter et konserveringssystem
DE602006011058D1 (de) Kontinuierliches backup
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
BRPI0812847A2 (pt) Uretano acrilado, composição, e, método para reticular pelo menos parcialmente a composição
BRPI0810008A2 (pt) Método para fabricar um cartucho de sorvente, e, cartucho de sorvente
CR10705A (es) Anticuerpos para linfotoxina-alfa
BRPI0810710A2 (pt) Método para estabilização de uma proteína.
BRPI0718974A2 (pt) Copolímero, e, método para preparar um copolímero
BRPI0716554A2 (pt) compostos de mÉtodos para agentes rotulados de 18f
EP1988081A4 (en) BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE
BRPI0916539A2 (pt) filtro para um artigo para fumar, artigo para fumar
FI20065217A7 (fi) Menetelmä synkronoidun aikakeskiarvon laskemiseksi
BRPI0813366A2 (pt) Método para executar uma combustão.
BRPI0718324A2 (pt) Métodos para o tratamento de depressão.
BRPI0823029A2 (pt) Conjunto, e, método para fazer um conjunto.
BRPI0813319A2 (pt) Método para preparar um composto, e, composto
FI20090190L (fi) Liiketoimintamenetelmä kenkien myymiseksi
BRPI0715339A2 (pt) Método para proliferar células lak.
BRPI0921468A2 (pt) métodos de limpeza de despejo reduzido para sistemas relacionados a poço de óleo
BRPI0923215A2 (pt) método para fabricar um composto.
ES1063735Y (es) Testero para persiana
ES1063721Y (es) Petaca plurifuncional para articulos de fumador.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TAKEDA PHARMACEUTICALS U.S.A., INC (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]